Drug Type Small molecule drug |
Synonyms Mevidalen Hydroxybenzoate, D1 PAM, LY-3154207 |
Target |
Mechanism D1 receptor modulators(Dopamine D1 receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H29Cl2NO3 |
InChIKeyXHCSBQBBGNQINS-DOTOQJQBSA-N |
CAS Registry1638667-79-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | US | 26 Aug 2024 | |
Alzheimer Disease | Phase 2 | JP | 26 Aug 2024 | |
Lewy Body Disease | Phase 2 | US | 09 Nov 2017 | |
Lewy Body Disease | Phase 2 | CA | 09 Nov 2017 | |
Lewy Body Disease | Phase 2 | PR | 09 Nov 2017 | |
Parkinson Disease | Phase 2 | US | 09 Nov 2017 | |
Parkinson Disease | Phase 2 | CA | 09 Nov 2017 | |
Parkinson Disease | Phase 2 | PR | 09 Nov 2017 |
Phase 1 | 80 | xwljnaqzyn(lrpucfhjmw) = Blood pressure increased when taking mevidalen, but there was considerable overlap with patients taking placebo, and vital signs normalized with repeated dosing bttcaofhtn (uplhukszlg ) View more | - | 19 Oct 2021 | |||
Phase 2 | 344 | Placebo (Placebo) | dbcfijceol(ydcamprstv) = oblcqgpfou cwsmfzriil (zpfapnpxew, fzemftvjdb - aknwyoonuw) View more | - | 23 Jul 2021 | ||
(30 mg LY3154207) | dbcfijceol(ydcamprstv) = ghiecqljsw cwsmfzriil (zpfapnpxew, rvxpwzjhau - fnnswkyhyf) View more | ||||||
Phase 1 | - | LY3154207 15 mg | jdvmqyolou(obaurefatf) = jzjpufirlm zmghogfjdi (ffazsvjmmk ) | Positive | 09 Apr 2019 | ||
LY3154207 30 mg | jdvmqyolou(obaurefatf) = cgddquimwj zmghogfjdi (ffazsvjmmk ) |